Nuclear receptors and their relevance to diseases related to lipid metabolism

Current Opinion in Pharmacology

Volumn 5, Issue 2 SPEC. ISS., 2005, Pages 171-176

  Berkenstam, Anders ^a   Gustafsson, Jan Åke ^b  

^a Karo Bio   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BICALUTAMIDE; CELL NUCLEUS RECEPTOR; FARNESOID X RECEPTOR; GLUCOCORTICOID ANTAGONIST; GLUCOCORTICOID RECEPTOR; GLUCOSE; LEVOTHYROXINE; LIVER X RECEPTOR; MIFEPRISTONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; PLACEBO; RAGAGLITAZAR; RALOXIFENE; RETINOID; ROSIGLITAZONE; SPIRONOLACTONE; STEROID; STEROID RECEPTOR; THYROID HORMONE; THYROID HORMONE DERIVATIVE; THYROID HORMONE RECEPTOR; XENOBIOTIC AGENT;

ADRENAL INSUFFICIENCY; ARTICLE; BONE ATROPHY; CARBOXY TERMINAL SEQUENCE; CARCINOGENICITY; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CUSHING DISEASE; DRUG POTENCY; DRUG TARGETING; DYSLIPIDEMIA; FLUID RETENTION; GLUCOSE BLOOD LEVEL; HEART FAILURE; HEART RATE VARIABILITY; HUMAN; HYPERTENSION; HYPOTHYROIDISM; IN VITRO STUDY; IN VIVO STUDY; LIPID METABOLISM; MUSCLE ATROPHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PERIPHERAL EDEMA; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; RECEPTOR AFFINITY; SIDE EFFECT; THYROTROPIN RELEASE; WEIGHT GAIN; X RAY CRYSTALLOGRAPHY;

EID: 15044364708     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2005.01.003     Document Type: Review

References (33)

1. H. Gronemeyer J.-A. Gustafsson V. Laudet Principles for modulation of the nuclear receptor superfamily Nat Rev Drug Discov 3 2004 950-964
2. C.L. Smith B.W. O'Malley Coregulator function: A key to understanding tissue specificity of selective receptor modulators Endocr Rev 25 2004 45-71
3. L. Nagy J.W. Schwabe Mechanism of the nuclear receptor molecular switch Trends Biochem Sci 29 2004 317-324
4. G. Benoit M. Malewicz T. Perlmann Digging deep into the pockets of orphan nuclear receptors: Insights from structural studies Trends Cell Biol 14 2004 369-376
5. K.H. Pearce M.A. Iannone C.A. Simmons J.G. Gray Discovery of novel nuclear receptor modulating ligands: An integral role for peptide interaction profiling Drug Discov Today 9 2004 741-751
6. A. Tailleux G. Torpier H. Mezdour J.C. Fruchart B. Staels C. Fievet Murine models to investigate pharmacological compounds acting as ligands of PPARs in dyslipidemia and atherosclerosis Trends Pharmacol Sci 24 2003 530-534
7. G.J. Grover K. Mellstrom L. Ye J. Malm Y.L. Li L.G. Bladh P.G. Sleph M.A. Smith R. George B. Vennstrom et al. Selective thyroid hormone receptor-beta activation: A strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability Proc Natl Acad Sci USA 100 2003 10067-10072
8. L. Ye Y.L. Li K. Mellstrom C. Mellin L.G. Bladh K. Koehler N. Garg A.M. Garcia Collazo C. Litten B. Husman et al. Thyroid receptor ligands. 1. Agonist ligands selective for the thyroid receptor beta1 J Med Chem 46 2003 1580-1588
9. G.J. Grover D.M. Egan P.G. Sleph B.C. Beehler G. Chiellini N.H. Nguyen J.D. Baxter T.S. Scanlan Effects of the thyroid hormone receptor agonist GC-1 on metabolic rate and cholesterol in rats and primates: Selective actions relative to 3,5,3'-triiodo-L-thyronine Endocrinology 145 2004 1656-1661
10. J.D. Baxter P. Webb G. Grover T.S. Scanlan Selective activation of thyroid hormone signaling pathways by GC-1: A new approach to controlling cholesterol and body weight Trends Endocrinol Metab 15 2004 154-157
11. H. Yki-Jarvinen Thiazolidinediones N Engl J Med 351 2004 1106-1118
12. F. Monzani N. Caraccio M. Kozakowa A. Dardano F. Vittone A. Virdis S. Taddei C. Palombo E. Ferrannini Effect of levothyroxine replacement on lipid profile and intima-media thickness in subclinical hypothyroidism: A double-blind, placebo- controlled study J Clin Endocrinol Metab 89 2004 2099-2106
13. T. Nagasaki M. Inaba Y. Henmi Y. Kumeda M. Ueda H. Tahara S. Sugiguchi S. Fujiwara M. Emoto E. Ishimura et al. Decrease in carotid intima-media thickness in hypothyroid patients after normalization of thyroid function Clin Endocrinol(Oxf) 59 2003 607-612
14. T.W. von Geldern N. Tu P.R. Kym J.T. Link H.S. Jae C. Lai T. Apelqvist P. Rhonnstad L. Hagberg K. Koehler et al. Liver-selective glucocorticoid antagonists: A novel treatment for type 2 diabetes J Med Chem 47 2004 4213-4230
15. F.C. Zusi M.V. Lorenzi V. Vivat-Hannah Selective retinoids and rexinoids in cancer therapy and chemoprevention Drug Discov Today 7 2002 1165-1174
16. K. Haan New stopwatch for PPAR developers BioCentury 2004 A9
17. M.F. Saad S. Greco K. Osei A.J. Lewin C. Edwards M. Nunez R.R. Reinhardt Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects: A 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm Diabetes Care 27 2004 1324-1329
18. R. Chakrabarti R.K. Vikramadithyan P. Misra J. Hiriyan S. Raichur R.K. Damarla C. Gershome J. Suresh R. Rajagopalan Ragaglitazar: A novel PPAR alpha PPAR gamma agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models Br J Pharmacol 140 2003 527-537
19. B. Charbonnel J. Dormandy E. Erdmann M. Massi-Benedetti A. Skene PROactive Study Group The prospective pioglitazone clinical trial in macrovascular events (PROactive): Can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients Diabetes Care 27 2004 1647-1653
20. P. Tontonoz D.J. Mangelsdorf Liver X receptor signaling pathways in cardiovascular disease Mol Endocrinol 17 2003 985-993
21. G. Zollner P. Fickert A. Fuchsbichler D. Silbert M. Wagner S. Arbeiter F.J. Gonzalez H.U. Marschall K. Zatloukal H. Denk M. Trauner Role of nuclear bile acid receptor, FXR, in adaptive ABC transporter regulation by cholic and ursodeoxycholic acid in mouse liver, kidney and intestine J Hepatol 39 2003 480-488
22. H. Wittenburg M.A. Lyons R. Li G.A. Churchill M.C. Carey B. Paigen FXR and ABCG5/ABCG8 as determinants of cholesterol gallstone formation from quantitative trait locus mapping in mice Gastroenterology 125 2003 868-881
23. M. Wagner P. Fickert G. Zollner A. Fuchsbichler D. Silbert O. Tsybrovskyy K. Zatloukal G.L. Guo J.D. Schuetz F.J. Gonzalez et al. Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice Gastroenterology 125 2003 825-838
24. J. Huuskonen M. Vishnu C.R. Pullinger P.E. Fielding C.J. Fielding Regulation of ATP-binding cassette transporter A1 transcription by thyroid hormone receptor Biochemistry 43 2004 1626-1632
25. N. Levin E.D. Bischoff C.L. Daige D. Thomas C.T. Vu R.A. Heyman R.K. Tangirala I.G. Schulman Macrophage liver X receptor is required for antiatherogenic activity of LXR agonists Arterioscler Thromb Vasc Biol 25 2005 135-142
26. T. Temelkova-Kurktschiev M. Hanefeld The lipid triad in type 2 diabetes - prevalence and relevance of hypertriglyceridaemia/low high-density lipoprotein syndrome in type 2 diabetes Exp Clin Endocrinol Diabetes 112 2004 75-79
27. J.M. Maglich J. Watson P.J. McMillen B. Goodwin T.M. Willson J.T. Moore The nuclear receptor CAR is a regulator of thyroid hormone metabolism during caloric restriction J Biol Chem 279 2004 19832-19838
28. M. Qatanani J. Zhang D.D. Moore Role of the constitutive androstane receptor in xenobiotic induced thyroid hormone metabolism Endocrinology 2004 [Epub ahead of print]
29. Y. Kamei H. Ohizumi Y. Fujitani T. Nemoto T. Tanaka N. Takahashi T. Kawada M. Miyoshi O. Ezaki A. Kakizuka PPARgamma coactivator 1beta/ERR ligand 1 is an ERR protein ligand, whose expression induces a high-energy expenditure and antagonizes obesity Proc Natl Acad Sci USA 100 2003 12378-12383
30. H. Greschik R. Flaig J.P. Renaud D. Moras Structural basis for the deactivation of the estrogen-related receptor gamma by diethylstilbestrol or 4-hydroxytamoxifen and determinants of selectivity J Biol Chem 279 2004 33639-33646
31. Z. Wang G. Benoit J. Liu S. Prasad P. Aarnisalo X. Liu H. Xu N.P. Walker T. Perlmann Structure and function of Nurr1 identifies a class of ligand-independent nuclear receptors Nature 423 2003 555-560
32. N. Heldring M. Nilsson B. Buehrer E. Treuter J.-A. Gustafsson Identification of tamoxifen-induced coregulator interaction surfaces within the ligand-binding domain of estrogen receptors Mol Cell Biol 24 2004 3445-3459
33. M.A. Iannone C.A. Simmons S.H. Kadwell D.L. Svoboda D.E. Vanderwall S.J. Deng T.G. Consler J. Shearin J.G. Gray K.H. Pearce Correlation between in vitro peptide binding profiles and cellular activities for estrogen receptor-modulating compounds Mol Endocrinol 18 2004 1064-1081